Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

Fig. 2

Prognostic analysis of MAP17 expression in NSCLC. a Analysis of the risk (left) and survival probability (right) based on MAP17 expression in lung cancer tumours from the Lung Metabase [38]. Red: high risk; Green: low risk. b Analysis of the risk (left) and survival probability (right) based on MAP17 expression in lung cancer tumours from the NCI directors challenge consortium database [39]. Red: high risk; Green: low risk. c Analysis of survival probability based on MAP17 expression in adenocarcinoma or squamous carcinoma lung cancer tumours from the Lung Metabase database. D) Analysis of survival probability based on adjuvant radiotherapy treatment based on MAP17 expression in lung cancer tumours from the Lung Metabase database (n = 1053)

Back to article page